TheEdgeResearch
Home / Stocks / MYNDF

MYND Life Sciences Inc. (MYNDF)

OTC Healthcare Biotechnology
$0.01 ▲ +0.00%
Market Cap
$657,843
Sector
Healthcare
Industry
Biotechnology
Beta
0.98
52-Wk Range
0.0081-0.0675
CEO
Wilfred A. Jefferies
Country
CA
Currency
USD

MYND Life Sciences Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Port Coquitlam, BC, CA. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $657,843. On trailing twelve-month figures it carries a trailing P/E of -2.18, a net margin of 0.0%. Its beta of 0.98 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-2.18
Price / Sales
0.00
Price / Book
-0.66
EV / EBITDA
-3.51
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
-0.60
Current ratio
0.14
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
0
IPO date
2021-09-22
Headquarters
Port Coquitlam, BC, CA
About MYND Life Sciences Inc.

Headquartered in Kelowna, Canada, MYND Life Sciences Inc. operates as a neuro-pharmaceutical enterprise focused on creating innovative therapies for depressive disorders. The company conducts scientific research and clinical trials across Canada and the United States to develop drugs derived from neuro-anti-inflammatory compounds. A significant part of their work involves the study and development of psilocin and psilocybin extracts, as well as their synthetic analogs.

Comparable companies

MYND Life Sciences Inc. is most often compared with the following Healthcare names:

BIXTBVAXFBZYRCPMVFAMDFGLWLFKNBIFSRNETHERTXTM
More research on MYNDF
MYNDF technical analysis MYNDF TheEdge Score Compare against peers
Open full interactive analysis & DCF →